Panacea Biotec Limited — Important, 30-05-2025: Updates

Panacea Biotec has announced a board meeting to consider the financial results for the quarter and half-year. The company reported a standalone net loss of ₹15.23 Cr and a consolidated net loss of ₹8.72 Cr for the year. Revenue from operations was ₹309.85 Cr (standalone) and ₹559.09 Cr (consolidated). The vaccines segment incurred losses, while formulations showed positive contribution. Panacea secured a new UNICEF order for 40 million doses of bivalent oral polio vaccine worth around ₹44 Cr. No dividend declared amid losses.